Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Forecast 2026–2030: Market Size, Trends And Growth Opportunities
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Poised To Hit $12.55 Billion By 2030 With A 14.8% CAGR
The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market has seen swift expansion in recent years. Its valuation is predicted to climb from $6.2 billion in 2025 to $7.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.7%. This historic growth can be attributed to several factors including the restricted availability of specialized cdmo services, increased investment in research and development for advanced therapies, the early adoption of gene and cell therapies, a rise in the occurrence of complex diseases, and the proliferation of small biotech startups.
The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market size is projected to experience swift expansion over the coming years. This market is set to reach $12.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.8%. Key drivers for this anticipated growth include advancements in scalable manufacturing technologies, an increase in collaborations between cdmos and pharmaceutical firms, the development of both autologous and allogeneic therapies, a growing worldwide need for personalized medicine, and market penetration into developing regions. Significant trends expected during this period involve a heightened demand for cdmo services in the development of advanced therapies, the broader application of gene, cell, and tissue engineered therapies, an increased emphasis on adherence to regulatory guidelines and quality benchmarks, the rise in outsourced production for biopharmaceutical entities, and the uptake of adaptable and scalable manufacturing platforms.
Get A Free Sample Report With In-Depth Market Insights:
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Expansion Drivers: What’s Shaping Future Growth?
The expanding volume of clinical trials is projected to propel the future growth of the advanced therapy medicinal products CDMO market. These trials are human-based research studies evaluating the safety and efficacy of medical interventions such as drugs, treatments, devices, or preventive measures. The number of clinical trials is increasing to meet the rising demand for innovative treatments and address a growing global disease burden. The utilization of advanced therapy medicinal products consequently elevates the demand for CDMO manufacturing services, leveraging specialized expertise and infrastructure. Clinical trial data is crucial for optimizing manufacturing, ensuring scalability, and maintaining quality to satisfy larger clinical and commercial needs. For instance, in July 2024, the Royal Pharmaceutical Society, a UK-based professional membership body, reported that 349,019 people were recruited to clinical trials in the UK during 2023/2024, an increase from 342,390 people in 2022/2023. Thus, the increasing number of clinical trials is a key factor driving the expansion of the advanced therapy medicinal products CDMO market.
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Segments: Where Is Growth Concentrated?
The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product: Gene Therapy, Cell Therapy, Tissue Engineered
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Indication: Oncology, Cardiology, Central Nervous System And Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology And Inflammation, Ophthalmology, Hematology
Subsegments:
1) By Gene Therapy: Viral Vectors, Non-Viral Vectors, Dna Or Rna-Based Products
2) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy
3) By Tissue Engineered: Skin Substitutes, Cartilage And Bone Tissue, Vascular Grafts And Organs
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Strategic Trends: What Defines The Next Growth Phase?
Leading firms within the advanced therapy medicinal products CDMO market are introducing sophisticated cell therapy manufacturing services aimed at resolving significant challenges in cell therapy production and accelerating their partners’ development timelines. These cell therapy manufacturing services represent contract development and manufacturing organization offerings, encompassing a spectrum of support from initial preclinical stages through advanced clinical trials and eventual market release. An example of this is Pluristem Therapeutics Inc., an Israel-based biotech company focused on cellular solutions, which in January 2024, unveiled PluriCDMO, a new division dedicated to providing cell therapy manufacturing. This division employs a proprietary bioreactor system enabling 3D cell multiplication, thereby supporting the creation of diverse cell types including stem cells, induced pluripotent stem cells, exosomes, and immune therapies. PluriCDMO aims to deliver high-quality, essential medicines to patients, ensuring exceptional batch-to-batch consistency in a scalable, cost-efficient way within good manufacturing practice environments.
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Key Participants And Competitive Landscape
Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions
View The Full Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Report:
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
